182 related articles for article (PubMed ID: 18264143)
1. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques.
Lioznov M; Badbaran A; Fehse B; Bacher U; Zander AR; Kröger NM
Bone Marrow Transplant; 2008 May; 41(10):913-6. PubMed ID: 18264143
[No Abstract] [Full Text] [Related]
2. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice.
Owen RG; Rawstron AC
Br J Haematol; 2005 Mar; 128(5):732-3; author reply 733-4. PubMed ID: 15725097
[No Abstract] [Full Text] [Related]
3. Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation.
Voena C; Malnati M; Majolino I; Fagà G; Montefusco V; Farina L; Santoro A; Ladetto M; Boccadoro M; Corradini P
Bone Marrow Transplant; 2003 Oct; 32(8):791-3. PubMed ID: 14520423
[TBL] [Abstract][Full Text] [Related]
4. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.
Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K
Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF
Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease monitoring in multiple myeloma.
Davies FE; Rawstron AC; Owen RG; Morgan GJ
Best Pract Res Clin Haematol; 2002 Mar; 15(1):197-222. PubMed ID: 11987924
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.
Martínez-Sánchez P; Montejano L; Sarasquete ME; García-Sanz R; Fernández-Redondo E; Ayala R; Montalbán MA; Martínez R; García Laraña J; Alegre A; Hernández B; Lahuerta JJ; Martínez-López J
Br J Haematol; 2008 Sep; 142(5):766-74. PubMed ID: 18637804
[TBL] [Abstract][Full Text] [Related]
9. [Detection of minimal residual disease in leukemia using flow cytometry].
Muroi K
Rinsho Ketsueki; 2008 Jun; 49(6):397-407. PubMed ID: 18646607
[No Abstract] [Full Text] [Related]
10. Minimal residual disease detection in myeloma: no more molecular remissions?
Rawstron AC
Haematologica; 2005 Oct; 90(10):1300B. PubMed ID: 16219557
[No Abstract] [Full Text] [Related]
11. Flow cytometry with anti HLA-antibodies: a simple but highly sensitive method for monitoring chimerism and minimal residual disease after HLA-mismatched stem cell transplantation.
Schumm M; Feuchtinger T; Pfeiffer M; Hoelle W; Bethge W; Ebinger M; Kuci S; Handgretinger R; Lang P
Bone Marrow Transplant; 2007 Jun; 39(12):767-73. PubMed ID: 17438586
[TBL] [Abstract][Full Text] [Related]
12. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.
de Tute RM; Jack AS; Child JA; Morgan GJ; Owen RG; Rawstron AC
Leukemia; 2007 Sep; 21(9):2046-9. PubMed ID: 17657223
[No Abstract] [Full Text] [Related]
13. Monitoring minimal residual disease in pediatric hematologic malignancies.
Campana D
Clin Adv Hematol Oncol; 2007 Nov; 5(11):876-7, 915. PubMed ID: 18185484
[No Abstract] [Full Text] [Related]
14. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL.
Fronkova E; Muzikova K; Mejstrikova E; Kovac M; Formankova R; Sedlacek P; Hrusak O; Stary J; Trka J
Bone Marrow Transplant; 2008 Aug; 42(3):187-96. PubMed ID: 18490915
[TBL] [Abstract][Full Text] [Related]
15. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.
Compagno M; Mantoan B; Astolfi M; Boccadoro M; Ladetto M
Methods Mol Med; 2005; 113():145-63. PubMed ID: 15968100
[TBL] [Abstract][Full Text] [Related]
16. Relative quantification of residual tumor cells by lightcycler real-time IgH PCR in autografted multiple myeloma patients.
Rimelen V; Ferrand C; Debecker A; Sovalat H; Tancredi C; Eidenschenk A; Hénon P
Leukemia; 2005 Mar; 19(3):492-5. PubMed ID: 15625553
[No Abstract] [Full Text] [Related]
17. Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions.
Ho C; Arcila ME
Semin Hematol; 2018 Jan; 55(1):13-18. PubMed ID: 29759147
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
19. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
20. Four-color flow cytometry detects minimal residual disease in leukemia.
Morrow T
Manag Care; 2006 Jan; 15(1):60-1. PubMed ID: 16502779
[No Abstract] [Full Text] [Related]
[Next] [New Search]
